# Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

> **NCT00610649** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 54 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** MK-8777
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00610649
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-20
- **Primary completion:** 2008-11-18
- **Final completion:** 2008-12-10
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00610649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00610649, "Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00610649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*